MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10545-016-9973-6

Медицинская библиотека · Journal of inherited metabolic disease · 2016

Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.

Hendriksz Christian J, Berger Kenneth I, Parini Rossella, AlSayed Moeenaldeen D, Raiman Julian, Giugliani Roberto, Mitchell John J, Burton Barbara K, Guelbert Norberto, Stewart Fiona, Hughes Derralynn A, Matousek Robert, Jurecki Elaina, Decker Celeste, Harmatz Paul R

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

To present long-term respiratory function outcomes from an open-label, multi-center, phase 3 extension study (MOR-005) of elosulfase alfa enzyme replacement therapy (ERT) in patients with Morquio A syndrome.

METHODS

In part 1 of MOR-005, patients initially randomized to ERT in the 24-week pivotal study (MOR-004) remained on their regimen (2.0 mg/kg/week or every other week); placebo patients were re-randomized to one of the two regimens. During part 2, all patients received elosulfase alfa 2.0 mg/kg/week. Respiratory function was one of the efficacy endpoints evaluated in MOR-005. Change from MOR-004 baseline to 120 weeks of treatment for the combined population was determined and compared with results from untreated patients from a Morquio A natural history study (MorCAP).

RESULTS

Maximum voluntary ventilation (MVV) improved up to week 72 and then stabilized; forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) increased continuously over 120 weeks. Mean increases in the modified per-protocol population was 9.2 % for FVC, 8.8 % for FEV1, and 6.1 % for MVV after 120 weeks. All patients ≤14 years showed respiratory improvements, presumably in part related to growth; however, these were greater in treated patients. For those >14 years, treated patients showed improvements, while deterioration occurred in untreated. Altogether, the improvements were significantly greater (P < 0.05) in treated patients.

CONCLUSIONS

Long-term ERT is associated with sustained improvements in respiratory function in Morquio A. In younger patients (≤14 years), some improvement may be ascribed to growth. In older patients, other mechanisms, e.g., decreased glycosaminoglycan storage, are likely involved.

Для цитирования: Hendriksz Christian J, Berger Kenneth I, Parini Rossella, AlSayed Moeenaldeen D, Raiman Julian, Giugliani Roberto, Mitchell John J, Burton Barbara K, Guelbert Norberto, Stewart Fiona, Hughes Derralynn A, Matousek Robert, Jurecki Elaina, Decker Celeste, Harmatz Paul R. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.. Journal of inherited metabolic disease. 2016. DOI: 10.1007/s10545-016-9973-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.